Time trends in breast cancer incidence and mortality in a mid-sized northeastern Brazilian city

BMC Public Health

Angela Maria da Silva¹  Matheus Macedo-Lima²  Margareth Rose Uchoa Rangel²  Carlos Anselmo Lima¹ 

[1] Hospital Universitário/Universidade Federal de Sergipe, Rua Claudio Batista s/n B Santo Antonio, Aracaju, SE, 49060-100, Brazil;Universidade Federal de Sergipe, Av Marechal Rondon s/n, São Cristovão, SE, 49100-000, Brazil

关键词: Time trends;    Cancer registry;    Mortality;    Incidence;    Breast cancer;   

Others  :  1162956
DOI  :  10.1186/1471-2458-12-883

 received in 2012-02-07, accepted in 2012-10-17,  发布年份 2012

【 摘 要 】

Background

Breast cancer incidence within an area is usually proportional to the area’s income level. High-income areas have shown the highest incidence rates and since 2003, negative trends. As for mortality, rates are often higher in low-income regions. The purpose of this study was to analyze trends in incidence and mortality in a capital city of a northeastern Brazilian state with an intermediate human development index.

Methods

Incidence data from the Population-Based Cancer Registry of Aracaju and mortality data from the Official State Database for the period 1996–2006 were used. Incidence and mortality crude and age-standardized rates were calculated. Time trends were obtained using the Joinpoint Regression Model.

Results

For the period studied, invasive breast cancer age-standardized incidence rates increased annually with an annual percentage change (APC) of 2.9 (95% CI: 1.2-4.6). Significant increasing trends were observed in groups aged 45–54 years (APC: 3.9, 95% CI: 1.4 to 6.6), and 55–64 years (APC: 5.6, 95% CI: 1.8 to 9.6). Age-standardized mortality rates did not show an increasing trend (APC: 3.0, (95% CI: -2.8 to9.1), except for the group aged 55–64 years (APC: 11.3, 95% CI: 1.1 to 22.4).

Conclusions

In the study community, breast cancer showed increasing incidence among women in the peri- and postmenopausal periods. However, mortality did not present increasing overall trends, except for among the group aged 55–64 years. For better outcomes, screening policies should focus on the peri- and postmenopausal periods of women’s lives to diagnose disease.

【 授权许可】

   
2012 Lima et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncoly 2007, 18(3):581-592.
• [2]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90CA.
• [3]Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA/ Ministério da Saúde. Rio de Janeiro: Estimativa 2012: incidência de câncer no Brasil; 2011.
• [4]Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S: Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007, 356(3):227-236.
• [5]Renard F, Van Eycken L, Arbyn M: High Burden of Breast Cancer in Belgium: Recent trends in incidence (1999–2006) and historical trends in mortality (1954–2006). Arch Public Health 2011, 69(1):2-11. BioMed Central Full Text
• [6]Pollán M, Ramis R, Aragonés N, Pérez-Gómez B, Gómez D, Lope V, García-Pérez J, Carrasco J, García-Mendizábal M, López-Abente G: Municipal distribution of breast cancer mortality among women in Spain. BMC cancer 2007, 7(1):78. BioMed Central Full Text
• [7]Porter PL: Global trends in breast cancer incidence and mortality. Salud Publ Mex 2009, 51(2):S141-S146.
• [8]Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford S, Howard BV, Johnson KC: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288(3):321-333.
• [9]Sprague BL, Trentham-Dietz A, Burnside ES: Socioeconomic disparities in the decline in invasive breast cancer incidence. Breast Cancer Res Treat 2010, 122(3):873-878.
• [10]Brasil PNUD: Atlas do Desenvolvimento Humano no Brasil. 2003. Available from:http://www.pnud.org.br/atlas/ webcite
• [11]Segi M: Cancer mortality for selected sites in 24 countries (1950-57). Sendai, Japan: Department of Public Health, Tohoku University of Medicine; 1960.
• [12]Doll R, Payne P, Waterhouse JAH (Eds): Cancer incidence in five continents. Vol I. Geneva: Union Internationale Contre le Cancer; 1960.
• [13]Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA/ Ministério da Saúde. Rio de Janeiro: Sistema de Registro de Câncer de Base Populacional - Sisbasepop; 2005.
• [14]Statistical Methodology and Applications Branch, Surveillance Research Program National Cancer Institute: Joinpoint Regression Program Version 3.5 [http://surveillance.cancer.org/joinpoint/download webcite]. 2011
• [15]Kim HJ, Fay MP, Feuer EJ, Midthune DN: Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000, 19(3):335-351.
• [16]Menvielle G, Kunst AE, van Gils CH, Peeters PH, Boshuizen H, Overvad K, Olsen A, Tjonneland A, Hermann S, Kaaks R: The contribution of risk factors to the higher incidence of invasive and in situ breast cancers in women with higher levels of education in the European prospective investigation into cancer and nutrition. Am J Epidemiol 2011, 173(1):26-37.
• [17]Esserman L, Shieh Y, Thompson I: Rethinking screening for breast cancer and prostate cancer. JAMA 2009, 302(15):1685-1692.
• [18]Fontenoy A, Leux C, Delacour-Billon S, Allioux C, Frenel J, Campone M, Molinié F: Recent trends in breast cancer incidence rates in the Loire-Atlantique, France: A decline since 2003. Cancer Epidemiol 2010, 34(3):238-243.
• [19]Lakkis NA, Adib SM, Osman MH, Musharafieh UM, Hamadeh GN: Breast cancer in Lebanon: Incidence and comparison to regional and Western countries. Cancer Epidemiol 2010, 34(3):221-225.
• [20]Hennis AJ, Hambleton IR, Wu SY, Leske MC, Nemesure B: Breast cancer incidence and mortality in a Caribbean population: Comparisons with African Americans. Int J Cancer 2009, 124(2):429-433.
• [21]Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA/ Ministério da Saúde. Rio de Janeiro: Programa Nacional de Controle do Câncer de Mama; 2011.
• [22]Jemal A, Center MM, DeSantis C, Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010, 19(8):1893-1907.
• [23]Bosetti C, Bertuccio P, Levi F, Chatenoud L, Negri E, La Vecchia C: The decline in breast cancer mortality in Europe: An update (to 2009). Breast 2012, 21(1):77-82.
• [24]DeSantis C, Siegel R, Bandi P, Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin 2011, 61(6):408-418.
• [25]Vostakolaei FA, Karim-Kos HE, Janssen-Heijnen MLG, Visser O, Verbeek ALM, Kiemeney LALM: The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Public Health 2011, 21(5):573-577.
• [26]Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D: Globocan 2008: cancer incidence and mortality worldwide. In IARC CancerBase No. 10 (version2.0). Lion: IARC; 2010.
• [27]Miller JW, King JB, Ryerson AB, Eheman CR, White MC: Mammography use from 2000 to 2006: state-level trends with corresponding breast cancer incidence rates. AJR Am J Roentgenol 2009, 192(2):352-360.
• [28]Wu JCY, Hakama M, Anttila A, Yen AMF, Malila N, Sarkeala T, Auvinen A, Chiu SYH, Chen HH: Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer. Breast Cancer Res Treat 2010, 122(2):553-566.